Sandhya Nair
Janssen Pharmaceutica
28 Papers
40 Citations
Sandhya Nair is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 17 publications.
Chat about Author
Papers
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Rafael Fonseca,Saad Z. Usmani,Maneesha Mehra,Mary Slavcev,Jianming He,Sarah Cote,Annette Lam,Jon Ukropec,Eric M Maiese,Sandhya Nair,Ravi Potluri,Peter M. Voorhees +11 more
TL;DR: A substantial proportion of patients with NDMM who received frontline therapy did not appear to receive a subsequent LOT, and high attrition rates underscore the need to use the most optimal treatment regimens upfront rather than reserving them for later LOTs in which the clinical benefit may decrease.
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J. Mease,Iain B. McInnes,Lai-Shan Tam,Kiefer Eaton,Steve Peterson,A. Schubert,Soumya D. Chakravarty,Soumya D. Chakravarty,Anna Parackal,Chetan S Karyekar,Sandhya Nair,Wolf-Henning Boehncke,Christopher T. Ritchlin +12 more
TL;DR: In this article, the authors compared guselkumab to other targeted therapies for psoriatic arthritis (PsA) for safety and joint and skin efficacy through network meta-analysis.
Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis:
Chris Cameron,C. Druchok,Brian Hutton,Brian Hutton,S. McElligott,Sandhya Nair,A. Schubert,Aaron Situ,Abhishek Varu,R. Villacorta +9 more
- 01 Apr 2019
TL;DR: Guselkumab was superior or comparable to other therapies for other efficacy outcomes and had a more favorable safety profile than most and has a favorable benefit–risk balance compared to moderate-to-severe psoriasis therapies.
22
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Katja Weisel,Thomas Martin,Amrita Krishnan,Sundar Jagannath,Anil Londhe,Sandhya Nair,Joris Diels,Martin Vogel,Jordan M. Schecter,Arnob Banerjee,Jesus G. Berdeja,Tonia Nesheiwat,Ashraf Garrett,Keqin Qi,Satish Valluri,Saad Z. Usmani,Kwee Yong +16 more
TL;DR: In this paper, Ciltacabtagene autoleucel (cilta-cel) was evaluated in the single-arm CARTITUDE-1 trial for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monoclonal antibody.
17
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
Rafael Fonseca,Thierry Facon,Mahmoud Hashim,Sandhya Nair,Jianming He,Eric A. Ammann,Annette Lam,Mark Wildgust,Shaji Kumar +8 more
TL;DR: In this paper , the authors used a partitioned survival model to compare overall survival with different treatment sequences in the first-line (1L) and second-line setting (2L) for NDMM patients.